The FDA approved a supplemental application for the recombinant HPV 9–valent vaccine (Gardasil 9, Merck), expanding the approved use of the vaccine to include women and men aged 27 through 45 years. This vaccine prevents certain cancers and diseases caused by the nine HPV types covered by the vaccine.
According to the CDC, every year about 14 million Americans become infected with HPV; about 12,000 women are diagnosed with, and about 4,000 women die from, cervical cancer caused by certain